Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: December 24, 2021
Correction to: Evaluation of drug‑drug interactions of pemigatinib in healthy participants.
Journal: European journal of clinical pharmacology
Published: August 26, 2021
Evaluation of drug-drug interactions of pemigatinib in healthy participants.
Journal: European journal of clinical pharmacology
Published: April 22, 2021
Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function.
Journal: British journal of clinical pharmacology
Published: April 20, 2021
Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order.
Journal: Neurology
Published: April 13, 2021
Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
Journal: Journal of clinical pharmacology
Published: October 06, 2020
An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Journal: Journal of clinical pharmacology
Published: February 27, 2020
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Journal: Journal of clinical pharmacology
Published: November 22, 2019
Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: August 13, 2019
Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
Journal: Journal of clinical pharmacology
Published: April 10, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026